|
Pharmaleads was set-up in December 2000 by a group of researchers from INSERM ( French National Medical Research Institute) led by Professor Bernard Roques assisted by Prof Marie-Claude Fournié-Zaluski.
Their teams have developed an internationally recognized expertise in the field of Zinc Metallopeptidases and in using their specific properties. Their numerous international publications cover key advancements of sciences in the understanding of a large number of proteases such as ACE, ECE, NEP, APN, APA, ….
Based on this strong know-how Pharmaleads has developed new patented products (substrates and inhibitors) from 2000 onwards.
In October 2008, Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain. In November
In November 2008, Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Pharmaleads SAS, announced the signature of an exclusive license agreement for the development, registration and commercialisation of a small molecule called Debio 0827 or PL37, about to enter phase I clinical trials. PL37/Debio 0827 is the first in a new class of painkillers that could be used in the treatment of chronic pain conditions, primarily in neuropathic pain.
Information on PL37/Debio 0827 can be found on our partner's website www.debiopharm.com
PHARMALEADS is pursuing its R&D activities in the field of pain and is developing promising strategies of enzyme inhibition in large and ill addressed therapeutic markets as inflamation, Alzheimer's disease and depression.
PHARMALEADS offers also original products lines and high value tailored services as:
 Detection and quantification of botulinum toxins A & B
High potent and selective substrates and/or inhibitors for HTS in ECE, NEP, APN, APA... domains
|
